Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Newlink Genetics
NLNK

Buy Newlink Genetics (NLNK) Stock

NLNK
See NLNK stock price and Buy/Sell Newlink Genetics with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
NLNK

Newlink Genetics (NLNK)

About Newlink Genetics (NLNK)

Lumos Pharma, Inc. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute ...Read more
Market Cap
$63.69M
1 Year High
$12.05
Volume
1 Year Low
$6.15
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch NLNK stock

Newlink Genetics Stock News

Newlink Genetics stock rating

What analysts recommend for NLNK stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
1

Newlink Genetics price target

What analysts think NLNK will be worth
Low $0
High $25
Current $0
Target $25

Events

List of events that could affect NLNK stock.
28Feb

Earnings data Q4 2019

07May

Earnings data Q1 2020

Newlink Genetics earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.33
-0.66
-0.99
Q3 2021
Q4 2021
Q1 2022
Q2 2022

Expected EPS
Q2 2022
-$0.99
Actual EPS
Q2 2022

Buy Newlink Genetics (NLNK) Stock

NLNK
See NLNK stock price and Buy/Sell Newlink Genetics with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch NLNK stock
  • Trixix avatar
  • Elle3 avatar
  • Railroadgirl avatar
  • Brenton89 avatar
  • Bhashu avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.